Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 6Carcinoma, Non-Small-Cell Lung 4Squamous Cell Carcinoma of Head and Neck 3Esophageal Squamous Cell Carcinoma 3Esophageal Neoplasms 3Carcinoma, Hepatocellular 3Breast Neoplasms 3Uterine Cervical Neoplasms 2Triple Negative Breast Neoplasms 2Recurrence 2Neoplasm Metastasis 2Nasopharyngeal Carcinoma 2Cholangiocarcinoma 2Biliary Tract Neoplasms 2Advanced Gastric Cancer 2Thoracic Neoplasms 1Solid Tumor 1Small Cell Lung Carcinoma 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Osteosarcoma 1Neoplasms by Site 1Mouth Neoplasms 1Lung Neoplasms 1Lung Diseases 1Liver Diseases 1Hodgkin Disease 1Hematologic Neoplasms 1Gestational Trophoblastic Disease 1Gastrointestinal Neoplasms 1

Interventions

camrelizumab 1Paclitaxel 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Advanced Esophageal Cancer × camrelizumab × Clear all
NCT03691090 2022-12-07

Study of SHR-1210 in Combination With Chemotherapy in Advanced Esophageal Cancer

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Completed
596 enrolled
Gastrointestinal

Advanced Esophageal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡